...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Updated List of BET inhibitors

BDAZ - It looked to me that all but maybe 3 of the 25 were focused on cancer disruption. RVX-208 was one of the 3. The other 2 didn't give enough of a discription for this simpleton  to determine what their target was.

It looks like Zenith has competition building but not so much for RVX.

tada

3
Apr 12, 2019 03:02PM
Share
New Message
Please login to post a reply